First Trust Advisors LP bought a new position in Exelixis Inc. (NASDAQ:EXEL) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 83,175 shares of the biotechnology company’s stock, valued at approximately $650,000.
A number of other institutional investors have also made changes to their positions in the company. GSA Capital Partners LLP purchased a new position in shares of Exelixis during the second quarter valued at approximately $117,000. Legal & General Group Plc raised its position in shares of Exelixis by 11.4% in the first quarter. Legal & General Group Plc now owns 33,497 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 3,440 shares during the period. Rathbone Brothers plc raised its position in shares of Exelixis by 5.3% in the second quarter. Rathbone Brothers plc now owns 20,000 shares of the biotechnology company’s stock valued at $156,000 after buying an additional 1,000 shares during the period. Bayesian Capital Management LP purchased a new position in shares of Exelixis during the first quarter valued at approximately $212,000. Finally, Quantitative Systematic Strategies LLC purchased a new position in shares of Exelixis during the second quarter valued at approximately $242,000. Institutional investors and hedge funds own 81.80% of the company’s stock.
Exelixis Inc. (NASDAQ:EXEL) traded up 2.93% during midday trading on Monday, reaching $13.33. The company’s stock had a trading volume of 4,438,750 shares. Exelixis Inc. has a 12-month low of $3.55 and a 12-month high of $15.58. The company’s 50-day moving average is $12.62 and its 200 day moving average is $8.24. The firm’s market cap is $3.07 billion.
Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 3rd. The biotechnology company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.11. The business earned $36.25 million during the quarter, compared to analysts’ expectations of $16.76 million. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. Exelixis’s revenue was up 353.7% on a year-over-year basis. Equities analysts forecast that Exelixis Inc. will post ($0.61) earnings per share for the current year.
Several brokerages have recently commented on EXEL. William Blair reiterated an “outperform” rating on shares of Exelixis in a research report on Thursday, September 15th. Cowen and Company reiterated a “buy” rating on shares of Exelixis in a research report on Wednesday, August 10th. S&P Equity Research increased their price objective on Exelixis from $13.41 to $15.57 in a research report on Wednesday, September 28th. Leerink Swann reiterated an “outperform” rating and set a $12.00 price objective on shares of Exelixis in a research report on Thursday, August 18th. Finally, Zacks Investment Research upgraded Exelixis from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Tuesday, September 13th. Six analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $13.51.
In other news, insider Gisela Schwab sold 42,338 shares of the business’s stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $11.00, for a total value of $465,718.00. Following the transaction, the insider now directly owns 174,354 shares in the company, valued at $1,917,894. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 5.90% of the stock is owned by insiders.
Exelixis, Inc is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ.
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.